In 2006, the US Food and Drug Administration (FDA) approved ranibizumab (Lucentis, Genentech), a vascular endothelial growth factor A (VEGF-A) antibody, providing a breakthrough treatment for AMD. This evidence concerns the gene VEGFA and age-related macular degeneration.